• +1-646-491-9876
    • +91-20-67278686

    Search

    Friedreich Ataxia - Pipeline Review, H1 2017

    Friedreich Ataxia - Pipeline Review, H1 2017

    • Report Code ID: RW0001767504
    • Category Pharmaceuticals
    • No. of Pages 85
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Friedreich Ataxia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

    Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

    Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Friedreich Ataxia - Overview
    Friedreich Ataxia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Friedreich Ataxia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Friedreich Ataxia - Companies Involved in Therapeutics Development
    Adverum Biotechnologies Inc
    BioMarin Pharmaceutical Inc
    Biovista Inc
    Cardero Therapeutics Inc
    Catabasis Pharmaceuticals Inc
    Edison Pharmaceuticals Inc
    Forward Pharma A/S
    Ixchel Pharma LLC
    Pfizer Inc
    ProQR Therapeutics NV
    RaNA Therapeutics Inc
    Reata Pharmaceuticals Inc
    Retrotope Inc
    Shire Plc
    STATegics Inc
    Voyager Therapeutics Inc
    Friedreich Ataxia - Drug Profiles
    ADVM-063 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AGIL-FA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVA-202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVA-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CAT-4001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTI-1601 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dextro epicatechin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dimethyl fumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon gamma-1b - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IXC-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JOT-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide to Activate Frataxin for Friedreich's Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omaveloxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QRX-604 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein 1 to Replace FXN for Friedreich Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-3250 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RT-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RT-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-622 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STSE-15 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vatiquinone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VYFXN-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Friedreich Ataxia - Dormant Projects
    Friedreich Ataxia - Discontinued Products
    Friedreich Ataxia - Product Development Milestones
    Featured News & Press Releases
    Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
    Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia
    Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
    Aug 05, 2015: Key Patent Granted For AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia
    Mar 24, 2015: Catabasis Pharmaceuticals to Present at International Ataxia Research Conference
    Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
    Feb 04, 2014: FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia
    Nov 04, 2013: Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations
    Jan 07, 2013: Edison Pharma Initiates Phase IIb Clinical Trial Of EPI-743 In Friedreich Ataxia
    Aug 01, 2012: Intellect Neurosciences Receives New Patent Allowance For OX1
    Aug 02, 2011: STATegics, Inc. Announces a Grant from Friedreich's Ataxia Research Alliance to Support Its Program to Develop Small Molecule Mimetics of Erythropoietin for the Treatment of Friedreich's Ataxia
    Apr 12, 2011: Intellect Neurosciences Files Orphan Drug Application In US For OX1 In Friedreich's Ataxia
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Friedreich Ataxia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H1 2017
    Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
    Friedreich Ataxia - Pipeline by Biovista Inc, H1 2017
    Friedreich Ataxia - Pipeline by Cardero Therapeutics Inc, H1 2017
    Friedreich Ataxia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
    Friedreich Ataxia - Pipeline by Edison Pharmaceuticals Inc, H1 2017
    Friedreich Ataxia - Pipeline by Forward Pharma A/S, H1 2017
    Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H1 2017
    Friedreich Ataxia - Pipeline by Pfizer Inc, H1 2017
    Friedreich Ataxia - Pipeline by ProQR Therapeutics NV, H1 2017
    Friedreich Ataxia - Pipeline by RaNA Therapeutics Inc, H1 2017
    Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Friedreich Ataxia - Pipeline by Retrotope Inc, H1 2017
    Friedreich Ataxia - Pipeline by Shire Plc, H1 2017
    Friedreich Ataxia - Pipeline by STATegics Inc, H1 2017
    Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H1 2017
    Friedreich Ataxia - Dormant Projects, H1 2017
    Friedreich Ataxia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Friedreich Ataxia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Adverum Biotechnologies Inc
    BioMarin Pharmaceutical Inc
    Biovista Inc
    Cardero Therapeutics Inc
    Catabasis Pharmaceuticals Inc
    Edison Pharmaceuticals Inc
    Forward Pharma A/S
    Ixchel Pharma LLC
    Pfizer Inc
    ProQR Therapeutics NV
    RaNA Therapeutics Inc
    Reata Pharmaceuticals Inc
    Retrotope Inc
    Shire Plc
    STATegics Inc
    Voyager Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//friedreich-ataxia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//friedreich-ataxia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//friedreich-ataxia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments